Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 328.50
Bid: 329.00
Ask: 330.50
Change: -3.00 (-0.90%)
Spread: 1.50 (0.456%)
Open: 328.00
High: 333.00
Low: 327.50
Prev. Close: 331.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

6 Jun 2023 15:59

RNS Number : 8498B
Oxford Biomedica PLC
06 June 2023
 

 

 

 

Oxford Biomedica

Total Voting Rights

 

 

Oxford, UK - 6 June 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company's issued share capital as at the close of business on 31 May 2023 consisted of 96,521,209 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 96,521,209.

 

The above figure (96,521,209) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREALKKESPDEFA
Date   Source Headline
5th Dec 201610:25 amRNSFindings Reported by Novartis on CTL-019 at ASH
5th Dec 20169:43 amRNSDirector/PDMR Shareholding
1st Dec 20169:27 amRNSTotal Voting Rights
29th Nov 20167:00 amRNSStrategic Alliance with Orchard Therapeutics
28th Nov 201610:06 amRNSDirector/PDMR Shareholding
8th Nov 20166:28 pmRNSGrant of options (Replacement)
8th Nov 20166:13 pmRNSGrant of options
1st Nov 201610:21 amRNSTotal Voting Rights
25th Oct 20164:40 pmRNSDirector/PDMR Shareholding
10th Oct 20167:21 amRNSPublication of RetinoStat® (OXB-201) Phase I study
6th Oct 20169:24 amRNSHolding(s) in Company
5th Oct 201610:17 amRNSHolding(s) in Company
4th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20168:16 amRNSAdmission to Trading and Total Voting Rights
29th Sep 201612:27 pmRNSResult of General Meeting and Directors Dealing
26th Sep 201611:00 amRNSDirector/PDMR Shareholding
13th Sep 20163:07 pmRNSPublication of Prospectus
13th Sep 20167:01 amRNSFUNDRAISING OF £10 MILLION
13th Sep 20167:00 amRNSINTERIM RESULTS FOR 6 MONTHS ENDED 30 JUNE 2016
1st Sep 201610:47 amRNSTotal Voting Rights
25th Aug 20162:22 pmRNSDirector/PDMR Shareholding
2nd Aug 20164:35 pmRNSPrice Monitoring Extension
2nd Aug 20169:32 amRNSTotal Voting Rights
28th Jul 20167:00 amRNSManufacturing Approvals and Expansion Completed
25th Jul 20169:56 amRNSDirector/PDMR Shareholding
8th Jul 201612:02 pmRNSPrice Monitoring Extension
4th Jul 20169:14 amRNSBlock Listing Return
4th Jul 20169:12 amRNSTotal Voting Rights
28th Jun 20164:40 pmRNSSecond Price Monitoring Extn
28th Jun 20164:35 pmRNSSecond Price Monitoring Extn
28th Jun 201612:07 pmRNSSecond Price Monitoring Extn
28th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201610:37 amRNSDirector/PDMR Shareholding
22nd Jun 201612:07 pmRNSSecond Price Monitoring Extn
22nd Jun 201612:02 pmRNSPrice Monitoring Extension
16th Jun 20164:40 pmRNSSecond Price Monitoring Extn
16th Jun 20164:35 pmRNSPrice Monitoring Extension
15th Jun 201612:07 pmRNSSecond Price Monitoring Extn
15th Jun 201612:02 pmRNSPrice Monitoring Extension
7th Jun 20161:14 pmRNSOxford BioMedica Annual General Meeting
7th Jun 20167:00 amRNSNew Non-Exclusive LentiVector Licence with MolMed
6th Jun 20163:29 pmRNSOXB to Present at Jefferies Healthcare Conference
2nd Jun 201610:05 amRNSR&D Partnership with Green Cross LabCell
2nd Jun 20169:30 amRNSTotal Voting Rights
24th May 201610:08 amRNSDirector/PDMR Shareholding
18th May 20167:00 amRNSDeferred Bonus Plan and LTIP Option Grants
17th May 20167:00 amRNSOxford BioMedica Appoints Corporate Broker
16th May 20169:23 amRNSDirector/PDMR Shareholding
16th May 20169:16 amRNSDirector/PDMR Shareholding
12th May 20167:00 amRNSOxford BioMedica Board Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.